TAXOTERE

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

Disponibbli minn:

SANOFI - AVENTIS ISRAEL LTD

Kodiċi ATC:

L01CD02

Għamla farmaċewtika:

CONCENTRATE FOR SOLUTION FOR INFUSION

Rotta amministrattiva:

I.V

Manifatturat minn:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

Grupp terapewtiku:

DOCETAXEL

Indikazzjonijiet terapewtiċi:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

Data ta 'l-awtorizzazzjoni:

2012-11-01